February 22, 2024
Memphasys tools up for more growth as leadership restructure sees Dr David Ali move to Acting CEO & Executive Director
In line with the global commercialisation strategy for our Felix™ device sperm separation device, Memphasys is proud to…
February 20, 2024
Advancing Artificial Insemination: The AI-Port Spring Trial Shows Promise
Innovations in artificial insemination (AI) are revolutionising the breeding industry, and Memphasys is at the…
February 7, 2024
The gathering storm: One in twenty men are infertile
"The human male was not a very fertile individual. Roughly one in 20 is infertile ... An old lecturer of mine used to…
February 6, 2024
Memphasys progresses freeze-free semen transporter
Reproductive technology company Memphasys has announced findings from a trial at a stud farm of its semen storage and…
February 2, 2024
Watch: The future of infertility treatment
Dr Ramya Jayaram addressed ASPIRE 2023, the 12th Congress of the Asia Pacific Initiative on Reproduction, to present…
February 2, 2024
Memphasys Expands Global Reach: Exclusive Distribution Agreements Signed for Canada and New Zealand
In a significant stride towards global expansion, we have announced an exclusive distribution agreement with Vitrolife…
January 24, 2024
FelixTM: Viewpoint from Japan
As the first major global commercial agreement to sell and distribute the FelixTM sperm separation device goes from…
January 16, 2024
Memphasys accelerates commercial approval for sperm-separation device
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…
December 6, 2023
Why FelixTM is big in Japan
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…
November 29, 2023
Fantastic Austrade support for Felix in Japan
Memphasys recently signed an exclusive distribution agreement with Vitrolife Japan KK, a subsidiary of the Vitrolife…